Ph1/2 FIH Study to assess AVZO-021 in Pts w/ Adv Solid Tumors
Phase I/II Clinical Trial
A PHASE 1/2 FIRST-IN-HUMAN STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF AVZO-021 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PATIENTS WITHADVANCED SOLID TUMORS (AVZO-021-1001)